Eli Lilly's stock drops as it slashes the price of Zepbound: Time to buy the dip?

This is no reason to panic.

A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Lilly Cuts Low-Dose Zepbound Price for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

Eli Lilly cuts Zepbound price to widen access for obesity drug

Dec 1 (Reuters) - Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound ...
Investor's Business Daily on MSN

Eli Lilly leads five stocks near buy points in divided market

Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks ...
Fierce Pharma

Lilly joins Novo in GLP-1 self-pay price cuts, lowering costs of single-dose Zepbound vials

In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...
24/7 Wall St.

Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump

Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally ...